Earnings Parade Rolls On With Palantir, Hims & Hers, Lattice, Axon and More 8/4/25
Closing Bell
00:00
Vertex Earnings Insights and IPO Market Volatility
This chapter analyzes Vertex Pharmaceuticals' recent earnings, praising their revenue while addressing the disappointment of the VX993 trial failure. It also covers Figma's stock decline post-IPO and discusses upcoming IPOs in the defense and space sectors, reflecting the tech market's volatility.
Transcript
Play full episode
